A joint study by Duchesnay and PeriPharm exposes critical gaps in access to innovative women's health products in Canada
BLAINVILLE, QC, May 29, 2025 /CNW/ - Duchesnay, member of Duchesnay Pharmaceutical Group (DPG), winner of the 2024 Life Sciences Innovation Award by ADRIQ, in collaboration with PeriPharm, is proud to announce the results of a landmark study exploring the accessibility of innovative women's health products in Canada. The research exposes systemic gaps and significant barriers that prevent Canadian women from accessing the innovative therapies they need.
The study found that of the 45 women's health products approved by the U.S. Food and Drug Administration (FDA) from January 1, 2003, to December 31, 2023, only 24 (53%) had received regulatory approval by Health Canada as of July 2024 and only 13 of these products are currently reimbursed publicly. 1
"These findings highlight a clear need to address inequities in how women's health is assessed, valued and prioritized," said Dany Hallé, Vice president, Commercial Affairs, DPG. "Striving to shape women's health ecosystem in Canada, we, at Duchesnay, believe that Canadian women deserve to have timely access to healthcare innovations."
Another important issue highlighted by researchers is the delays Canadian women face when it comes to approval and reimbursement processes for women's health therapies. Compared to the general access timeline for medications in Canada, the process for obtaining public coverage listing for women's health medications takes one year longer and can even exceed three years.
The study suggests that the current evidence-based Health Technology Assessment (HTA) framework may not fully capture the added value of innovative drugs in women's health, potentially contributing to delays or barriers in reimbursement and market access.
"This is a call to action," said Catherine Beauchemin, Ph.D., partner at PeriPharm. "This initiative marks an important first step toward improving access to innovations in women's health. To advance women's health outcomes in Canada, we must start by understanding their needs and preferences."
This study will serve as a benchmark and lay the groundwork for the development of a position paper co-written by leading experts in the domain addressing the challenges women ultimately face in the assessment of innovative medicines in Canada. This white paper would be hopefully available by year end.
1 In comparison, based on data between 2016 and 2020, 67% of all new active substance approval by FDA and/or EMA have been submitted to Health Canada.
ABOUT PERIPHARM
Founded in 2003, PeriPharm is a Canadian company specializing in pharmacoeconomics and outcomes research. The company's mission is to provide high-quality, diversified services to ensure optimal market access of health care innovations. PeriPharm's activity is built on the belief the best available therapies should be accessible to those who need it. As a leader in the field of health economics and data generation, PeriPharm has contributed to the success of several market access initiatives.
For more information about PeriPharm, please visit https://peripharm.com/en/.
Follow us on LinkedIn.
ABOUT DUCHESNAY
Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. Until recently, the company focused on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding.
Today, Duchesnay has broadened its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives. Believing that women around the world deserve to have access to specialized treatments for their conditions, Duchesnay now distributes its products internationally.
For more information about Duchesnay, please visit https://duchesnay.com/en/.
Follow us on LinkedIn.
ABOUT DUCHESNAY PHARMACEUTICAL GROUP
Duchesnay Pharmaceutical Group (DPG), with its affiliated companies, is headquartered in Blainville, Quebec. The Group consists of six pharmaceutical companies to meet the needs of patients in Canada, the U.S. and abroad. The companies are Duchesnay (Canada) and Duchesnay USA, both dedicated to women's health; Medunik Canada and Medunik USA, which provide treatments for rare and debilitating diseases; and Analog Pharma Canada and Analog Pharma, specializing in orphan generic medications. From its state-of-the-art manufacturing plant, DPG exports its innovative treatments to more than 50 countries.
DPG is one of the eight companies across the country chosen to participate in the Government of Canada's Global Hypergrowth Project. This appointment offers exclusive and personalized support for at least two years, in order to accelerate its growth to become an anchor firm in the Canadian economy.
DPG is the winner of the 2024 Life Sciences Innovation Award by ADRIQ, the Association for the Development of Research and Innovation of Quebec, which recognizes DPG's healthy workplace culture and commitment to pharmaceutical innovation, while DPG president Éric Gervais is the recipient of the 2024 Bernard-Landry Award by ADRIQ which acknowledges his impactful leadership on Quebec's research and innovation ecosystem.
DPG, through its proprietary research and development, and through exclusive partnerships, offers innovative treatments for a variety of medical conditions in women's health, urology, oncology and for rare diseases, plus lower-cost generic medications. DPG recognizes the dedication and professionalism of its employees and promotes a positive culture and flexible work environment. It is deeply committed to environmental responsibility and to giving back to the community through the support of various charitable organizations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Global News
6 hours ago
- Global News
Fraser Health wants whistleblowing ER doctor's lawsuit thrown out
Fraser Health has filed its response to a lawsuit from a whistleblowing emergency room doctor, and it wants to see the case dismissed. Dr. Kaitlin Stockton filed the suit earlier this year, claiming the health authority singled her out and retaliated against her after she publicly highlighted unsafe working conditions and hospital overcrowding. In November of last year, Stockton posted a notice in the ER waiting area of Eagle Ridge Hospital in Port Moody, warning patients of a shortage of capacity and resources. 1:10 Residents demand action after Delta Hospital emergency room closed overnight The suit claims that Stockton obtained permission from her local department head to post the notice, but that instead of addressing the problematic conditions, the health authority issued a statement calling the signs 'false,' then used CCTV footage to identify her, then to allegedly threaten her right to work in the hospital and to file a complaint with her regulator. Story continues below advertisement In its response to the suit, Fraser Health argues the court does not have the jurisdiction to hear the case, and says it should instead be dealt with through internal arbitration and mediation. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Stockton, however, told Global News she deliberately filed the suit in the court system with the goal of ensuring transparency. 'There's been huge public outcry about this case, and, unfortunately, it hasn't really moved the needle — we continue to see outrageously unsafe conditions for patients, for providers,' she said. 'This just puts extra scrutiny on that reality that we're facing right now, so I think it's in the best interest of Fraser Health to make this story go away.' Kathryn Marshall, Stockton's lawyer, said it's common for large companies and organizations to push for private arbitration, which she said can keep sensitive or controversial information from reaching the public. 0:56 Health-care worker assaulted at Port Moody hospital She contrasted that with the Canadian court system, in which both court proceedings and documents filed in court are open and accessible to the public. Story continues below advertisement 'So I think the question that needs to be raised to Fraser Health authority is why? Why are they trying to take this case out of the public sphere and have it dealt with behind closed doors? What's the reason?' she said. 'I think the answer is obvious to me, but I'd like to hear them say it, which is that they don't want public scrutiny or exposure on the issues that are in Dr. Stockman's case. They want to hide that.' Earlier this week, the emergency room at Delta Hospital was closed overnight with short notice, the latest in an ongoing series of ER closures and diversions throughout the province. 2:14 Former Fraser Health CEO's severance package sparks debate Those closures have typically been attributed to a shortage of available physicians or nurses. Stockton said she remains compelled to speak out publicly because the province's health care system is in 'freefall.' Story continues below advertisement 'We're no longer dealing with cracks in the foundation, like the roof has fallen in. This is unacceptable,' she said. 'And unfortunately, it's going to get worse unless health authorities and our government, first of all, acknowledge that there is a problem and secondly, pour all of their resources and energy into retaining the physicians and nurses that we have … who are leaving in record numbers because the workplace is not safe.' Asked for an interview, Fraser Health said it did not comment on pending litigation. –with files from Rumina Daya
Winnipeg Free Press
6 hours ago
- Winnipeg Free Press
Road to CFL hasn't been an easy one for Lions receiver Ayden Eberhardt
Resiliency has led Ayden Eberhardt to where he's at. The 27-year-old American receiver is enjoying a solid season with the B.C. Lions with 21 catches for 366 yards (17.4-yard average) and two touchdowns. But Eberhardt's path to the CFL hasn't been easy. He suffered a serious knee injury as a senior at Wyoming in 2021. Roughly three months after undergoing surgery, Eberhardt was diagnosed with Type 1 diabetes, a condition where the body's immune system destroys insulin-producing cells in the pancreas. 'If you'd told me when all of that was going down that I'd be playing pro football I probably would've questioned you a bit,' Eberhardt said. 'It (diagnosis) made rehab much trickier trying to figure out what I could eat to be able to recover. 'But I'm super thankful for everyone who's helped me get here. I love B.C. and playing in the CFL. It's all surreal.' Without insulin, glucose can't enter cells to be used for energy, which can lead to a dangerous sugar buildup in the bloodstream. Type 1 diabetics must take insulin either via injection or an insulin pump to manage their blood sugar. 'It's crazy because I went almost a year of recovery and testing foods to see what I could eat and how I must dose for different things,' Eberhardt said. 'It's definitely not easy and I'd say I'm still learning how to manage my sugar levels and make sure they're in line through practice and meetings and what can I eat that helps and doesn't help for games. 'But I think it has helped because as a professional athlete diet is very important and I have to think about mine quite a bit so it's beneficial knowing what I'm eating.' Eberhard allows himself cheat days to indulge in such treats as ice cream. But not sushi, at least for now. 'That breaks my heart because I absolutely love sushi,' he said. 'But rice messes me up quite a bit. 'The thing is you just have to know how to dose for it, that's kind of the motto I've been living by. I haven't taken that leap yet (for sushi) but I need to and I'm going to.' The six-foot-one, 200-pound Eberhardt signed with B.C. in February 2023 and played in two games as a rookie. He appeared in all 18 regular-season contests last year, recording 41 catches for 639 yards and two touchdowns. 'I felt comfortable last year but being 100 per cent honest, I think the game has slowed down for me now, whether it's coverages, what to look for, how to play against different leverages,' Eberhardt said. 'Obviously as time goes on you get more and more comfortable but I'd say this is probably the most comfortable I've been up here.' Another reason for Eberhardt's comfort level is familiarity. He has been teammates with Keon Hatcher Sr., Justin McInnis and Jevon Cottoy since arriving in B.C. and is in his second season with Stanley Berryhill III. And Canadian starter Nathan Rourke is in his second season after returning to B.C. last August following NFL stints with New England, the New York Giants and Atlanta. 'It's always nice to be able to pick each other's brain during practice and games if we (receivers) see something we weren't expecting or is new or different and how to play off of it,' Eberhardt said. 'Nate is a great leader who plays his butt off. 'You can see how much he puts into the game and how bad he really wants to win … and as other people on the team see that, it motivates everybody.' B.C. leads the CFL in net offence (408.3 yards per game) and stands second in passing (307.9). But the Lions are also fourth in rushing (106.4 yards) and boast the league's leading runner in James Butler (619 yards, 5.5-yard average, five TDs). 'Ayden is an outstanding high-character individual whose talent on the football field has been evident this season,' said Kenny Kim of Summit Athletes, Eberhardt's Florida-based agent. 'He plays the game with a lot of passion and grit. Thursdays Keep up to date on sports with Mike McIntyre's weekly newsletter. 'Ayden has made considerable strides in overcoming initial challenges. His commitment to hard work is yielding a lot of success and he'll continue to perform at a very high level.' But it's been a roller-coaster season for B.C. (3-5). The Lions have lost two straight heading into Thursday night's game versus the Hamilton Tiger-Cats (6-2) at Hamilton Stadium. 'We're so close,' Eberhardt said. 'We've shown flashes, I just don't think we've played a full complementary game as a team. 'I think once that happens and it clicks, then we'll be rolling and it will continue from there.' This report by The Canadian Press was first published Aug. 6, 2025.
Calgary Herald
6 hours ago
- Calgary Herald
'Disconnected': Province's ER wait numbers not whole story, says top Alberta doc
Article content By the numbers Article content In May, the rate was 19.2, in June it was 15.7 and in July it was 20.7. Article content At the U of A, it's 17 per cent on the year. The rate in May was 14, but dropped to 12.2 in June before ticking up to 12.9 July. Article content The Misericordia Hospital in west Edmonton has a rate of 16.4 per cent on the year, while at the Grey Nuns Hospital in southeast Edmonton, it's 13.2. Article content Government figures for July indicate the only Edmonton hospital with 'leaves without being seen' figures at 10 per cent or less was the Stollery Children's Hospital at the U of A site, where just under nine per cent went unseen before leaving. Article content At the Sturgeon hospital in St. Albert, figures ran under the provincial average; the LWBS rate is fairly steady over three years, up from seven per cent in 2023 to 8.5 per cent in 2025. Article content Article content A previous survey from the AMA indicated almost one in five Albertans — 18 per cent — surveyed who went to the emergency room left before receiving care, but the province pushed back on the survey, saying the AMA sample size of 1,120 respondents does not reflect the full range of patient experiences or health data. Article content One of the challenges Thirsk sees is space. In his 25-year medical career in Alberta, he's seen the number of hospitals in Edmonton stay static at four, while the population has doubled. Article content Asked about the 2024 cancellation of the planned South Edmonton Hospital, Jones's ministry said a projected cost of $4.9 billion cost would have made it the most expensive hospital in Canadian history. Article content 'It would have been an inefficient use of funds that could have been more effectively directed toward expanding existing infrastructure, increasing overall bed capacity, and better meeting the needs of Albertans,' said the ministry in its statement. Article content Article content Improvements slated for the health-care system in the Edmonton Corridor through Budget 2025 include an investment of $180 million over three years for health capital projects, with $2 million for planning new in-patient towers at Grey Nuns Hospital and the Misericordia Hospital, which will eventually add a total of 700 beds, Jones's office said. Article content Another $11 million is earmarked for planning for a new, stand-alone Stollery Children's Hospital, which is expected to eventually free up space within the University of Alberta Hospital for redevelopment, 'potentially allowing for the addition of a substantial number of adult in-patient beds,' the statement said. Article content Some $3 million is set aside to support plans to expand the Strathcona Community Hospital. Article content Of $17 million to develop urgent care centres across the province, two of those are earmarked for Edmonton. Specified for non-critical health needs, they're expected to reduce pressure on hospitals around the province, the ministry said.
